The Impact of Vaccination Status on the Severity of Pain Syndrome in COVID-19 Patients
Main Article Content
Abstract
COVID-19 has a lot of different symptoms, and pain syndrome is one of them. Getting a COVID-19 vaccine cut down on illnesses with symptoms and/or high viral loads. The study's goal is to find out how bad the pain syndrome is in people who have been vaccinated against COVID-19 and people who have not been immunized. A cross-sectional observational study was done on 304 COVID-19 patients from September 2021 to April 2023. The patients' ages ranged from 18 to 65. After they gave written permission, the people who took part in the study were given an electronic form with 20 questions. The study subjects were split into 5 groups based on their vaccine status: those who had not been vaccinated, those who had been partially vaccinated (≥ 14 days after dose 1 or < 14 days after dose 2), those who had been fully vaccinated (≥ 14 days after dose 2), those who had been vaccinated after the third dose, and those who had been vaccinated after the fourth dose. All subjects, vaccinated and not vaccinated, had pain syndrome symptoms, and there were no significant differences (P>0.05). A lot of people who weren't protected (40.2% of them) reported severe pain. In the group that got the fourth dose, however, it was not found at all (0%). It was (29.7%), (38.7%), and (39.1%) in the groups that had been partly vaccinated, fully vaccinated, and given the third dose of the vaccine, in that order. In conclusion, pain syndrome was found in all COVID-19 patients. The pain was much worse in patients who had not been vaccinated, but not in those who had gotten the fourth dose of the vaccine.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, Gallagher E, Thelwall S, Groves N, Dabrera G, Myers R, Campbell CNJ, Amirthalingam G, Edmunds M, Zambon M, Brown K, Hopkins S, Chand M, Ladhani SN, Ramsay M, Lopez Bernal J. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med 2022: 386:340-11.
II. Berger JR. COVID-19 and the nervous system. J Neurovirol 2020; 26(2):143-148.
III. Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, Simmons R, Cottrell S, Roberts R, O’Doherty M, Brown K. Effectiveness of the Pfizer-BioNTech and Oxford- AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 2021; 373:n1 088. doi: 10.1136/bmj.n1088
IV. Bio S. Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process. Guidance Document 2021.
V. Bolay H, Gül A, Baykan B. COVID-19 is a Real Headache! Headache 2020; 60(7):1415-1421. doi: 10.1111/head.13856.
VI. Chen LL, Hsu CW, Tian YC, Fang JT. Rhabdomyolysis associated with acute renal failure in patients with severe acute respiratory syndrome. Int j clin pract 2005; 59(10):1162- 6.
VII. Fan CK, Yieh KM, Peng MY, Lin JC, Wang NC, Chang FY. Clinical and laboratory features in the early stage of severe acute respiratory syndrome. J Microbiol Immunol Infec 200 6; 39(1):45-53.
VIII. Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, Groome MJ, Huppert A, O'Brien KL, Smith PG, Wilder-Smith A. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. The Lancet 2022; 399(10328):924-944. doi: 10.1016/S0140-6736(22) 00152-0
IX. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, Lewis N, Natarajan K, Stenehjem E, Grannis SJ, Han J, McEvoy C, Ong TC, Naleway AL, Reese SE, Embi PJ, Dascomb K, Klein NP, Griggs EP, Konatham D, Kharbanda AB, Yang DH, Fadel WF, Grisel N, Goddard K, Patel P, Liao IC, Birch R, Valvi NR, Reynolds S, Arndorfer J, Zerbo O, Dickerson M, Murthy K, Williams J, Bozio CH, Blanton L, Verani JR, Schrag SJ, Dalton AF, Wondimu MH, Link-Gelles R, Azziz-Baumgartner E, Barron MA, Gaglani M, Thompson MG, Fireman B. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep 2022; 71(7):255-263. doi: 10.15585/mmwr.mm710 7e2
X. Ferdinands JM, Thompson MG, Blanton L, Spencer S, Grant L, Fry AM. Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research. Vaccine 2021; 39(28): 3678-3695.
doi: 10.1016/j.vaccine.2021.05.011
XI. Freij BJ, Gebara BM, Tariq R, Wang AM, Gibson J, El-Wiher N, Krasan G, Patek PM, Levasseur KA, Amin M, Fullmer JM. Fatal central nervous system co-infection with SARS- CoV-2 and tuberculosis in a healthy child. BMC pediatrics 2020; 20:1
XII. Ge E, Li Y, Wu S, Candido E, Wei X. Association of pre- existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study. PLoS One 2021; 16(10):e025 8154.
doi: 10.1371/journal.pone.0258154
XIII. Guadarrama-Ortiz P, Choreno-Parra JA, Sanchez-Martinez CM, Pacheco-Sanchez FJ, Rodriguez-Nava AI, Garcia- Quintero G. Neurological aspects of SARS-CoV-2 infection: mechanisms and manifestations. Front Neurol 2020; 11:1039.
XIV. Gülsen, Askin, Yigitbas BA, Uslu B, Drömann D, Kilinc O. The Effect of Smoking on COVID-19 Symptom Severity: Systematic Review and Meta-Analysis. Pulm Med 2020. doi: 10.1155/2020/7590207
XV. He Y, He Y, Hu Q, Yang S, Li J, Liu Y, Hu J. Association between smoking and COVID-19 severity: A multicenter retrospective observational study. Medicine (Baltimore) 2022; 101(29):e29438. doi: 10.1097/MD.0000000000029438
XVI. Hoong CW, Amin MN, Tan TC, Lee JE. Viral arthralgia a new manifestation of COVID-19 infection? A cohort study of COVID-19-associated musculoskeletal symptoms. Int J Infect Dis 2021; 104:363-369. doi: 10.1016/j.ijid.2021.01.031
XVII. Jena D, Sahoo J, Barman A, Gupta A, Patel V. Musculoskeletal and neurological Pain Symptoms Among Hospitalized COVID-19 Patients. Am J Phys Med Rehabil 2022; 101(5):411-416. doi: 10.1097/PHM.00000000000 01969
XVIII. Mangalmurti N, Hunter CA. Cytokine storms: understanding COVID-19. Immunity 2020; 53(1):19-25. doi: 10.1016/j.immuni.2020.06.017
XIX. Ng OT, Marimuthu K, Lim N, Lim ZQ, Thevasagayam NM, Koh V, Chiew CJ, Ma S, Koh M, Low PY, Tan SB. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines with and Without Boosters in Singapore. JAMA Netw Open 2022; 5(8):e2228900. doi: 10.10 01/jamanetworkopen.2022.28900
XX. Oguz‐Akarsu E, Gullu G, Kilic E, Dinc Y, Ursavas A, Yilmaz E, Zarifoglu M, Karli N; Pandemic Study Team. Insight into pain syndromes in acute phase of mild‐to‐moderate COVID‐19: Frequency, clinical characteristics, and associated factors. Eur J Pain 2022; 26(2):492-504. doi: 10.100 2/ejp.1876
XXI. Ouassou H, Kharchoufa L, Bouhrim M, Daoudi NE, Imtara H, Bencheikh N, ELbouzidi A, Bnouham M. The Pathogenesis of Coronavirus Disease 2019 (COVID-19): Evaluation and Prevention. J Immunol Res 2020; 2020:1357983. doi: 10.1155/2020/1357983
XXII. Paniz-Mondolfi A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, Sordillo EM, Fowkes M. Central nervous system involvement by severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2). J Med Virol 2020; 92(7):699- 702. doi: 10.1002/jmv.25915
XXIII. Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, Keefe F, Mogil JS, Ringkamp M, Sluka KA, Song XJ, Stevens B, Sullivan MD, Tutelman PR, Ushida T, Vader K. The revised IASP definition of pain: Concepts, challenges, and compromises. Pain 2020; 161(9):1976-1982. doi: 10.1097/j.pai n.0000000000001939
XXIV. Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J, Olsho LE, Caban-Martinez AJ, Fowlkes AL, Lutrick K, Groom HC. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med 2021; 385(4):320-329. doi: 10.1056/NEJMoa21070 58
XXV. Tran VT, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort. BMJ Med 2023; 2(1).
XXVI. Tsai LK, Hsieh ST, Chao CC, Chen YC, Lin YH, Chang SC, Chang YC. Neuromuscular disorders in severe acute respiratory syndrome. Arch Neuro 2004; 61(11):1669-73. doi: 10.1001/archneur.61.11.1669
XXVII. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395(10234):1417-1418. doi: 10.1016/ S0140-6736(20)30937-5
XXVIII. Wang JT, Sheng WH, Fang CT, Chen YC, Wang JL, Yu CJ, Chang SC, Yang PC. Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis 2004; 10(5):818-24.
XXIX. Wong D, Whaley L. Clinical Handbook of pediatric nursing, 2nd edn. St. Louis: C.V. Mosby 1986; 373.
XXX. World Health Organization (WHO). The pfizer bioNTech (BNT162b2) COVID-19 vaccine: What you need to know. Updated 21 January 2022, pursuant to updated interim recommendations, 2021.
XXXI. World Health Organization. The Oxford/AstraZeneca (ChAdOx1-S [recombinant] vaccine) COVID-19 vaccine: what you need to know. World Health Organization: Geneva, Switzerland 2022.